ImmunityBio
IBRX
61 hedge funds and large institutions have $39.8M invested in ImmunityBio in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 23 increasing their positions, 17 reducing their positions, and 8 closing their positions.
35% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 17
21% more capital invested
Capital invested by funds: $32.8M → $39.8M (+$6.98M)
0.15% less ownership
Funds ownership: 13.74% → 13.59% (-0.15%)
5% less funds holding
Funds holding: 64 → 61 (-3)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$570K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$237K |
| 3 |
JP Morgan Chase
New York
|
+$201K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$80.8K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$62.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$367K |
| 2 |
Millennium Management
New York
|
-$237K |
| 3 |
Goldman Sachs
New York
|
-$162K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$152K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$131K |
IBRX Hedge Fund Activity: Q3 2018 in Review
61 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q3 2018, worth a combined $39.8M — up 21% from $32.8M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of IBRX and 5 opened new positions — a net loss of 3 holders — while 17 trimmed existing stakes and 23 added.
The largest buyer was Renaissance Technologies, adding an estimated $570K. The largest seller was Morgan Stanley, cutting an estimated $367K.
- 61 institutional investors held ImmunityBio (IBRX) as of Q3 2018, down from 64 in Q2 2018.
- Funds reported $39.8M of ImmunityBio stock for Q3 2018, up 21% quarter-over-quarter.
- 5 funds opened new ImmunityBio positions in Q3 2018 and 8 closed out, a net change of -3 holders.
- The largest ImmunityBio buyer in Q3 2018 was Renaissance Technologies, an estimated $570K added.
- The largest ImmunityBio seller in Q3 2018 was Morgan Stanley, an estimated $367K sold.
Based on aggregated 13F filings for Q3 2018.